In a landmark in paediatric oncology research, children with high-risk neuroblastoma across Europe and North America will be treated together for the first time, following the award of $1.3M to fund a new trans- Atlantic clinical trial led by Dr Yael Mossé of Children’s Hospital of Philadelphia and Dr Dominique Valteau-Couanet of Institute Gustave Roussy in France, investigating the ALK inhibitor Lorlatinib in the treatment of children with newly diagnosed high-risk neuroblastoma, a deadly childhood cancer that mainly affects children under the age of five.
Research into new treatments for hard to cure children’s cancers has not made much progress in the last few decades.
By working together with other non-profit organizations on an international level we’ll accelerate development of new treatments for children with cancer.
Some cancers, like neuroblastoma which took Zoé’s life in 2013, are so rare that research will never move forward unless it is done on an international level.
Zoé4life has joined a partnership under the leadership of Solving Kids Cancer UK and several other non-profit organizations in Europe and in North America in order to join forces to finance research projects together.
Together, we will succeed in Solving Kids Cancer!